Munster Technological University

SWORD - South West Open Research
Deposit
Dept. of Management & Enterprise Publications

Management & Enterprise

2015-11-07

Irish GMS cost projections and its implications between 2016 and
2026
Aisling Conway Lenihan
Cork Institute of Technology, aisling.conway@cit.ie

Noel Woods
Centre for Policy Studies, University College Cork, 6 Bloomfield Terrace, Western Road, Cork, Ireland

Follow this and additional works at: https://sword.cit.ie/dptmeart
Part of the Economic Policy Commons, Health and Medical Administration Commons, Health
Economics Commons, Health Policy Commons, Health Services Administration Commons, Health
Services Research Commons, and the Medical Humanities Commons

Recommended Citation
Lenihan AC, Woods N (2015) Irish GMS Cost Projections and Its Implications between 2016 and 2026.
Pharmacoeconomics 1:101. Doi: 10.4172/2472-1042.1000101

This Article is brought to you for free and open access by the Management & Enterprise at SWORD - South West
Open Research Deposit. It has been accepted for inclusion in Dept. of Management & Enterprise Publications by an
authorized administrator of SWORD - South West Open Research Deposit. For more information, please contact
sword@cit.ie.

Lenihan and Woods, Pharmacoeconomics 2015,
1:1
http://dx.doi.org/10.4172/pe.1000101

Pharmacoeconomics
Research Article

Open access journal

Irish GMS Cost Projections and Its Implications between 2016 and 2026
Conway Lenihan A1* and Woods N2
1Department
2Centre

of Management and Enterprise, Cork Institute of Technology, Rossa Avenue, Bishopstown, Cork City, Ireland

for Policy Studies, University College Cork, 6 Bloomfield Terrace, Western Road, Cork, Ireland

*Corresponding

Author: Aisling ConwayLenihan, Department of Management and Enterprise, Cork Institute of Technology, Rossa Avenue, Bishopstown Cork, Ireland,
Tel: +353214335924; E-mail: aisling.conway@cit.ie
Received date: September 18, 2015; Accepted date: October 26, 2015; Published date: November 07, 2015
Copyright: © 2015 Lenihan AC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract
Introduction: Ireland had one of the highest pharmaceutical spends per capita in the EU in 2012. The General
Medical Services (GMS) scheme is the largest community drug scheme in Ireland with approximately 40% of the
population eligible for free drugs and appliances in 2012. The total cost of GMS prescriptions increased by 414%
between 1998 and 2012. This paper projects Irish GMS cost from 2016 to 2026 and examines the implications of the
estimated impact on GMS expenditure.
Method: Central Statistics Office (CSO) population projections (2013) and HSE-PCRS GMS population
prescription data (2012) were used to develop four variables; population, GMS coverage, average cost per claimant
and claims rate. A Monte Carlo Simulation (MCS) model simulated the effect of these four variables on GMS costs,
by health board region, age cohort and sex.
Results: Irish population is projected to grow by approximately 10% between 2012 and 2026. The over 70s
population is estimated to grow by 64% with the proportion of males growing by 72%. GMS expenditure is estimated
to increase by 64%, from €1.1 billion in 2016 to €1.8 billion by 2026. Age is a key driver of GMS expenditure,
specifically those aged under 11 and over 70. The MCS results project that males, the Mid-Western and SouthEastern regions are driving GMS costs in the under 11s. Females, Midlands and Southern regions are driving GMS
costs in the over 70s.
Conclusion: Population growth coupled with an aging population will impact future GMS costs. Targeted GMS
policy changes such as co-payment charges, reference pricing, and generic substitution can help to contain future
GMS expenditure.
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Introduction
In 2012, Ireland spent 14% of total government expenditure on
healthcare which is comparable with the European Union (EU)
average, EU28. The Netherlands had the highest proportion at 20%
and Cyprus had the lowest proportion at 8%. Irish health spending
accounted for 8.9% of Gross Domestic Product (GDP), just above the
EU28 average of 8.7%. Netherlands recorded the highest value at 11.8%
and Romania the lowest at 5.6% [1]. According to a 2015 Organisation
for Economic Co-Operation and Development (OECD) report, Ireland
spent 1.3% less on health between 2007 and 2013 [2]. Irish
pharmaceutical expenditure per capita relative to other OECD
countries has increased significantly since 2000. Ireland’s position has
moved from 20th highest of 27 countries in 2000 to 3rd highest of 25
countries in 2010. In 2010, Irish per capita spending on
pharmaceuticals was the highest in the EU and was 34% above the EU
average [3]. The Irish government has introduced cost containment
measures during the economic crisis to combat this trend such as copayment charges for patients, GMS eligibility criteria, reference pricing
and generic substitution promotion [4]. Despite these cost
containment measures, Irish pharmaceutical spending per capita in
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2012 was the third highest amongst EU countries at €500, 40% above
the EU average (€350) [1].
There are eleven community drug schemes in Ireland, where a
person has entitlement to free or subsidised healthcare. The four most
expensive schemes are the General Medical Services Scheme (GMS),
Drug Payments Scheme (DPS), High Tech Drug Scheme (HTDS) and
Long Term Illness (LTI) scheme. The GMS scheme is the largest
community drug scheme in Ireland. 40.40% of the population
(1,853,877 persons) were eligible for the GMS (also known as medical
card scheme) in 2012, the highest it has been since data was published
in 1996 (1,252,385-34.5%) [5]. Any eligible GMS person is entitled to
free medicines and appliances. Eligibility is determined by income
guidelines and persons who are affected by certain medical conditions.
The GMS scheme is financed by the state with a contribution from
each GMS eligible person. Since October 2010, each person on the
scheme incurred a €0.50 charge for every prescription item dispensed
up to a maximum of €10 per family per month. This was subsequently
increased to €1.50 in 2013 and is currently €2.50 per prescription item
up to a maximum of €25 per family per month.
GMS coverage rates (proportion of the population who has a
medical card) peaked in 2012 and have fallen to 1,849,380 (40.3%) in
2013 and to 1,804,376 (39.3%) in July 2014. This decrease may be
partly attributed to a reduction in the number of discretionary medical
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cards issued, which decreased from 63,126 in 2012 to 50,294 in 2013
[6]. Discretionary medical cards are awarded when significant medical
costs are incurred as a result of illness and are unable without undue
hardship to arrange GP medical and surgical services for themselves
[7]. The total cost of GMS prescriptions has increased from €249
million in 1998 to €1.28 billion in 2012, a 414% increase (various
annual PCRS Reports – 1998-2012). GMS prescription expenditure
rose rapidly after 2000. It increased by 290% from approximately €328
million in 2000 to €1.28 billion in 2012. GMS expenditure accounted
for 9% of the overall health budget in 2012 [8]. There are number of
factors identified in the literature that influence drug expenditure;
population, population aging, inflation, price effects, volume effects,
mix of drugs, sex and age [9-12].
Modelling health and drug expenditure varies considerably
internationally. A number of studies on health expenditure projections
based on historical trends have been carried out in the US [13-15]. The
three studies estimated national health expenditure based on
assumptions around economic (varying levels of economic growth)
and demographic variables for a 10 year period. Another US study
developed projections on drug expenditure and incorporated historical
trends in drug expenditure and expected changes in the drugs market
that may influence drug expenditure in 2015 [16]. A French study
forecasted national drug expenditure based on demographic and
epidemiological factors out to 2029, using a Markovian microsimulation model [17]. A Swedish study forecasted drug expenditure
in the region of Stockholm over a two year period, 2010-2011. They
used a linear regression analysis and applied it to historical drug sales
between 2006 to 2009 [18]. Based on expert opinion and a review of
the literature, a Monte Carlo Simulation (MCS) was deemed to be the
most appropriate model to use.
A 2014 study by Conway et al [19] projected GMS costs for Ireland
in five year intervals to 2026, using 2008 Central Statistics office (CSO)
population projections. This study estimated that GMS expenditure is
estimated to increase from €1.1 billion in 2011 to €1.9 billion by 2026.
The conclusions drawn were that age (<11 and >70), females and the
Midlands region were found to have the most significant effect on
future GMS costs in Ireland. Since then, the CSO [20] has revised its
population projections downwards and following the onset of the
financial crisis, the Irish government has introduced cost containment
measures. This paper adds to the literature by utilising updated CSO
population projections and 2012 GMS population prescription data.
The aim of this paper is to project Irish GMS cost from 2016 to 2026
and to examine the implications of the estimated impact on GMS
expenditure.

Method
To estimate GMS costs to 2026, we used a MCS model to simulate
various scenarios, using the latest CSO population projections and
2012 Health Service Executive-Primary Care Reimbursement Service
(HSE-PCRS) population GMS prescription data. From this data, four
variables were developed; population, GMS coverage rates, claims rate
and average cost per claimant. Three scenarios were formulated for
each variable; low variable growth (best case scenario - minimum),
average variable growth (most likely scenario - mean) and high
variable growth (worst case scenario - maximum).
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CSO population data
The CSO regional population projections 2016-2031 [20] provided
updated projections based on the 2011 Irish census. Data was detailed
by year of age, sex, county and region, incorporating assumptions
around mortality, fertility, international and internal regional
migration. The revised downward CSO population projections are
mainly driven by a fall in fertility. We aggregated the population data
into ten HSE cohorts so comparisons can be made with earlier research
[19]. An adjustment factor based on the 2011 census was applied as
three of the CSO regions (Border, Mid-East, Dublin) did not conform
to three of the old health board regions (North-West, North-East,
Eastern). There are eight regions (Eastern, South-Eastern, Southern,
Western, Mid-West, Midlands, North-West and North-East) within the
old health board structure in Ireland.

GMS coverage rates
GMS coverage rates are the proportion of the population who have
a medical card. 2012 mean coverage rates by the old health board
region, sex and age cohort were estimated using the 2012 PCRS annual
report and CSO population projections. The minimum, mean and
maximum coverage rates were estimated using historical data between
1996 and 2012. These three scenarios formed the basis of projections
for 2016, 2021 and 2026. The projected mean population was used to
estimate the coverage rates and the number of eligible persons for each
scenario in 2016, 2021 and 2026.

GMS HSE-PCRS database
HSE-PCRS population GMS dataset (2009-2012) and N=60 million
for each year. The data is detailed per prescription item (observation).
There are 40 variables in the database, of which seven are specific to
this research. These include; HSE Local Health Office (LHO) number,
year of age, sex, dispense number and total cost (ingredient cost, Value
Added Tax (VAT) and dispensing fee). Any person can register with
their LHO (32 offices) to determine eligibility for the GMS scheme. A
unique dispense number is allocated to each GMS claimant for all
prescription items in an individual year. A claimant is a person who
has a GMS medical card and makes a claim on that card. If a claimant
is issued a replacement medical card within any specific year, they will
be allocated a new dispense number. The data was aggregated and
analysed by the old health board region (8). The data was cleaned as
some data had no sex or age. The year of age variable was aggregated
into the eleven HSE age cohorts ranging <5’s to the >75’s. For the
purpose of comparison, the age cohorts, <5 and 5-11 were summed
together for the four variables. Data management and analysis was
carried out in Microsoft Excel and R-Studio version 2.15.3. HSE-PCRS
population GMS dataset (2009-2012), combined with the annual 2012
PCRS report [5] was used to formulate the average cost per claimant
and claims rate variables.

Claims rate
The claims rate is the proportion of the GMS population who make
a claim. 1,853,877 held medical cards in Ireland in 2012, of which,
1,649,950 made a claim (claims rate=89%). Historical national and
regional claims rates were calculated to determine lower and upper
bound values around the mean claims rate. Between 2005 and 2012,
the lowest national claims rate was 88% and the highest national claims
rate was 95% (2007 levels) and these formed the minimum and
maximum scenarios respectively. The mean claims rate in 2012 was
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scaled by the minimum national and regional claims rate values to
determine the lower bound claims rate scenario 2012 by region, sex
and age cohort. 2007 claims rate values by region, sex and age cohort
were taken as the upper bound scenario for 2012 [19]. For this analysis,
the claims rate was assumed to remain at 2012 estimated levels (3
scenarios) over the lifetime of the projections.

Average cost per claimant
The average cost per claimant is the total cost of claimants divided
by the number of claimants and this was calculated using the 2012
HSE-PCRS population dataset. The average cost per claimant variable
was updated using HSE-PCRS 2009 to 2012 population data and this
formed the basis of our projections whereas the previous research [19]
was based on a sample 2007 HSE-PCRS GMS database. Historical
average cost per claimant data was determined from the HSE-PCRS
population database between 2009 and 2012. There is considerable
variation in the data year on year. The minimum, mean and maximum
growth rates between 2009 and 2012 were calculated by age cohort and
sex. This variation may be explained by the Irish economic crisis, an
increase in GMS eligibility rates and health expenditure cuts.
Therefore, a four year average cost per claimant between 2009 and
2012 was deemed appropriate given the variability in the data and this
formed the most likely scenario for 2012 and the base for projections
of this variable. Upper bound and lower bound 2012 scenarios were
estimated around the mean cost per claimant. Initially, various
percentiles and the inter-quartile range were determined, but showed
significant variation in the data. Therefore, we estimated lower and
upper bounds for 2012 around the mean cost per claimant (mean ±
5%).
The four year average cost per claimant ± 5% formed the basis of
projections between 2016 and 2026. For average cost per claimant
projections, the minimum, mean and maximum annual growth rates
were determined between 2009 and 2012. As the historical data
showed significant variation between 2009 and 2012, projections based
on these growth rates were not deemed appropriate. A four year
average of the health inflation rate between 2009 and 2012 was
calculated (2%) and this was applied annually between 2012 and 2026
[21]. The minimum 2012 average cost per claimant (scenario 1) values
by region, sex and age cohort were uniformly increased by 2% to
determine 2016 scenario 1 average cost per claimant by region, sex and
age cohort. For example, a male in the Eastern region in the 0-11 age
cohort has an average cost per claimant value of €107.80 in 2012. This
value was increased annually by 2% up to 2016 to estimate the average
cost per claimant of €116.69 for 2016. The following formula (Eq1) was
applied to each of the 160 cells (age cohorts (10), sex (2) and regions
(8));
Min ac per claimant 2016=min ac per claimant 2012 (1+0.02)4 (1)
This methodology was applied to all three scenarios to determine
three 2016 scenarios. Using the same methodology average cost per
claimant 2016 (3 scenarios) and 2021 (3 scenarios) was increased by
2% uniformly across region, sex and age cohort to determine average
cost per claimant 2021 and 2026 respectively.

MCS model was employed due to the uncertainty around the input
parameters. The input parameters are population, coverage, claims rate
and average cost per claimant based on 2012 data. MCS was employed
to propagate the parameter uncertainty through 100,000 iterations.
Each input variable is comprised of age cohorts (10), sex (2) and
regions (8) giving a total of 160 cells to be modelled for each variable.
The dependent variable is the projected total GMS cost for 2016, 2021
and 2026. Taking a large number of simulations (100,000), gives an
approximation to the true distribution of projected cost. The equation
(Equation: 3) used for simulations is;
Probable cost=Expected cost+error (3)
In order to prepare the data for Monte Carlo Simulations, the
probability and cumulative probability of finding a person within each
region, sex and age cohort class were calculated. A macro was written
in Visual Basic Editor in Microsoft Excel to run the simulations. It’s
important to assign an appropriate probability distribution to
uncertain variables in developing a comprehensive MCS model [22]. A
normal distribution was applied to estimate costs to allow for
uncertainty in the model. The Central Limit Theorem was applied,
which states that the sum of random variables will be approximately
distributed [23]. The MCS results were imported into Minitab for
analysis. All statistical analyses were performed using Minitab
statistical package (Minitab 17).

Results
This section includes a descriptive analysis followed by an empirical
analysis.

National population projections
The population of Ireland is estimated to grow from 4.6 million to
5.0 million, an increase of almost 10% between 2012 and 2026 in
Figure 1. The female population is estimated to grow by 10.5%,
whereas the male population is estimated to grow by 9.5%. The
updated population projections in Table 1 are more conservative than
the Conway et al. [19] projections.
Year

Current Projections

Conway et
Projections

2012

4.6

4.7

2016

4.7

5.1

2021

4.9

5.4

2026

5.0

5.7

al

(2014)

Population

Source: [19]

Table 1: Comparison current population projections (Million) with
Conway et al (2014) Projections.

The Cost projection model (Eq 2) is as follows;
Total Cost=f (Population, GMS Coverage, AC per Claimant, Claims
Rate) (2)
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GMS coverage projections

Figure 1: Estimated Population Growth 2012–2026.

GMS coverage projections were produced by old health board
region, sex, age cohort and three scenarios in five year intervals
between 2016 and 20263. Figure 3 estimates GMS coverage rates will
lay between 29% and 43% in 2016, 31% and 43% in 2021 and 33% and
46% in 2026. Coverage rates are estimated to be lower in 2016 due to
slower population growth. The 2012 estimates of the mean claims rate
and the average cost per claimant are available in the supplementary
information file. The 2012 average cost per claimant for a male and
female in the >75 age category is 15 and 18 times the average cost per
claimant of a male and female in the 0-11 age category in the Eastern
region, highlighting the variation in cost by age cohort.

The elderly population is those aged 65+ but this paper focuses on
the over 70’s population as this age group is entitled to free medical
care on the GMS scheme. The over 70’s include two age cohorts, 70-74
and >75’s. The over 70s population is estimated to grow by 64%
between 2012 and 2026 in Figure 2. The male population is estimated
to grow by 72.2% and the female population is expected to grow by
57.6%1.

Figure 3: GMS Coverage Projections (%) 2016–2026.

GMS cost projections

Figure 2: Estimated Population Growth for those aged 70 and over,
2012–2026.

GMS cost projections are estimated to be €1.1 billion in 2016, €1.4
billion in 2021 and €1.8 billion in 2026 (most likely scenario) as
illustrated in Figure 4. Lower CSO population projections based on
lower fertility rates contributed to more conservative GMS cost
projections.

The dependency ratio (ratio of population aged 65+ to the
population aged 18-64) indicates the likely impact of population aging.
The dependency ratio is estimated to increase from 0.21 in 2016, to
0.24 in 2021 and 0.27 in 2026. The inverse (ratio of population aged
18-64 to the population aged 65+) shows those of working age who
support the older population of 65+. It decreases from 4.54 in 2016, to
3.95 in 2021 to 3.49 in 2026.

Regional population projections
Regional population is expressed as a proportion of the national
population2. In 2012, we estimated that 35.3% of the population live in
the Eastern region but this is projected to increase to 37.2% by 2026.
Three regions, Midlands, North-West and the South-East region are
estimated to grow slightly between 2012 and 2016 and decrease
thereafter. The remaining four regions are forecasting a population
decrease over the lifetime of the projections.
1
2
3

Figure 4: GMS Cost (€m) Projections 2016–2026.

Personal Communication: with a CSO population Statistician advised that males are experiencing higher growth rates than females in
older age cohorts, as there more males than females in earlier age cohorts.
See Supplementary Information file for region (population proportion - %) Population Projections 2012 – 2026
See Supplementary Information file for 2026 GMS projections, most likely scenario.
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Monte carlo simulation results - descriptive and statistical
analysis
The descriptive analysis of 100,000 simulations for 2016, 2021 and
2026 is detailed in Table 2. There is considerable variation in the cost
results with 25% of the data lying below €46.02 and 75% of the data
lying above €253.43 in 2016. The average cost per claimant is estimated
to be €249.96 with the median estimated to be €106.22. The histogram
plots the distribution of cost with a higher frequency of claimants
having a lower average cost per claimant as illustrated in Figure 5.

In Figure 6, females, the Midlands and Southern regions are driving
costs in the over 70s. These results were also found in 2026.
Year

♯ of Simulations

Mean

St. Dev

Min

Q1

2016

100,000

249.96

348.24

21.25

46.02

2021

100,000

307.45

418.28

24.58

53.49

2026

100,000

384.13

508.22

28.14

62.3

Table 2: Descriptive Analysis of Average Cost per Claimant (€) 2016–
2026 (Scenario 2- most likely scenario).

Average cost per claimant (€) by sex and region – Scenario 1Scenario 3
In Figure 7, the Midlands and the Southern regions are the most
expensive and the Eastern and Western regions are the least expensive
regions for all three scenarios. Females are driving costs more than
males for all three scenarios. The under 11s and increasing age are
driving costs for all three scenarios. Similar trends were found for sex
and age cohort in 2021 and 2026. In 2021 and 2026, the South-Eastern
and the Midlands regions are estimated to be the most expensive and
the North-Eastern and Eastern regions are estimated to be the least
expensive regions.

Figure 5: Histogram of Cost and Main effects Plot, Mean Scenario,
2016.
The histogram reiterates the descriptive analysis in Table 2, there is
significant variation in cost with the lowest claim of €21.25 and the
highest claim of €1573.57 in 2016. In Figure 5, the main effects plot
examines the differences between the three categorical variables; old
health board region, sex and age cohort. Sex is showing no main effect
with all regions showing some effect except Eastern and NorthEastern. Age cohorts show the greatest response, especially under 11s,
65-69 and over 70s. Researchers further analysed these age groups and
found that males, Mid-Western and South-Eastern regions are driving
costs in the under 11s age group as illustrated in Figure 6.
Figure 7: Average Cost per Claimant by Age Cohort, Region and
Sex, and Scenarios 1-3 2016.

Discussion

Figure 6: Main effects Plot by Sex and Old Health Board Region <11
and >70, Mean Scenario, 2016.
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The key findings of this research are; population growth, significant
growth in the over 70s population, age, sex and region and the
implications they will have in fuelling GMS costs. Irish population is
projected to grow by approximately 10% between 2012 and 2026. The
over 70s population is estimated to grow by 64% with males over 70
estimated to grow by 72% over the projection period. A combination
of falling rates of fertility and mortality produces a greater proportion
of older people in society.An aging population will significantly
contribute to overall GMS costs and has the potential to cause an
increase in GMS coverage rates, claims rates and average cost per
claimant. According to a WHO report, a key driver of health care costs
is growth in the overall size of the population. Population aging is also
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a driver of health care costs, but not to the same extent [24]. An Irish
study on aging reported that the dependency ratio was 0.18 in 2011
rising to 0.23 in 2021 [25]. Our estimates for 2021 show a similar
finding, with a dependency ratio of 0.24. This Irish study argued the
inverse of the dependency ratio was more informative and they
estimated a value of 5.7 in 2011 falling to 4.4 in 2021 [25]. In our study,
the inverse is estimated to be 3.95 in 2021. An aging population,
leading to an increased dependency ratio, will put financial pressures
on future health costs. A French study found an increase in aging
population and changes in health status will increase French drug
expenditure annually by between 1.1% and 1.8% for the over 25s [17].
A US study estimated health spending will grow on average by 5.8%
annually to $2.4 trillion between 2012 and 2022 based on a sluggish
economic recovery in 2013 coupled with an expansion in coverage due
to the Affordable Care Act and an aging population [13]. Two US
studies projected drug expenditure and one study projected 12% to
14% increases in US total drug expenditures in clinics, and 5% to 7%
increases in hospitals [16]. The other study predicted drug expenditure
(ambulatory and hospital) would increase by 2% in 2010 and 4% in
2011 [18]. The current GMS cost projections are more conservative
than the previous Irish projections [19]. Previous research estimated
GMS cost projections will rise to €1.3 billion in 2016, €1.6 billion in
2021 and €1.9 billion in 2026. This research estimated GMS cost
projections will rise to €1.1 billion in 2016, €1.4 billion in 2021 and
€1.8 billion in 2026 [19].
This research [19] found that females, age (≤ 11 and ≥ 70) and the
Midlands region were driving GMS costs out to 2026. This paper
confirms those findings and contributes the following; males, the MidWestern and South-Eastern regions are driving GMS costs in the under
11s in 2016. Females, Midlands and Southern regions are driving GMS
costs in the over 70s in 2016. Our results show that younger male
children (≤ 11 years) are a driver of GMS costs in Ireland. This may be
explained by a higher incidence of drug prescribing amongst male
children. An Irish study investigating prescribing antibiotics trends in
a paediatric sub-population found that male participants (0-4 age
cohort) were more likely to receive an antibiotic prescription than
female participants [26]. A Spanish study examined how gender and
age influenced prescription drug use and found a higher prevalence of
prescription drugs in males aged 0-4 and 5 to 14 years of age [11]. A
Swedish study found more drugs were dispensed amongst males under
10 years [27]. In 2011, a new government was formed in Ireland with
an objective of implementing a single-tier health service through the
introduction of universal health insurance with free medical care for all
[28]. In Budget 2015, the Irish government partially met this objective,
by announcing free General Practitioner (GP) care for all children
under 6 years of age. As this is one of the most expensive age groups,
the Irish government may have been better advised to implement this
policy in a less expensive age group such as adolescents as a pilot
measure. Females over 70 years are driving GMS costs in Ireland. In
Spain [11], Sweden [27] and British Colombia [29], there is a higher
incidence of prescribing amongst females compared to males. The
Spanish study found drug prescribing is 23% higher in females than
males and that age is statistically more significant than sex (P<0.05)
[11]. In British Colombia, they found that population aging only
explained 1 point of the observed annual drug expenditure growth
4
5

[29]. The drug expenditure growth is largely explained by the increase
in the age/sex specific numbers of prescriptions filled per patient and
mix of products selected per prescription.
The Midlands region is the most expensive region and the Eastern
region is the least expensive region for GMS costs. Upon further
investigation at age cohort level, GMS costs differ across the eight
regions. The Mid-Western and South-Eastern are the most expensive
regions for the under 11s, the Midlands for the over 70s and the
Eastern region is the least expensive region for both age cohorts. A
high prevalence of chronic conditions in the Midlands region [30]
coupled with Usher et al. [31] findings that the Midlands and the MidWestern regions had the highest prescribing rates for type 1 and type 2
diabetes may explain high GMS expenditure in this region.
In terms of policies on cost containment, in November 2012, a three
year agreement was formulated between the Irish Pharmaceutical
Healthcare Association (IPHA), the Department of Health and the
HSE. The agreement applies to medicines prescribed and reimbursed
on the community drugs scheme, including the GMS. This agreement
led to reductions in the cost of in-patent and off-patent
pharmaceuticals [32]. It was widely reported that this agreement would
yield over €400 million for the Irish state over three years. The Irish
government estimated €16 million in drug savings in 2012 across all
community drug schemes4, €116 million in 2013, €136 million in 2014
and €150 million in 2015 [33]. According to a recent WHO report [4],
the agreement resulted in actual savings of €190 million. Co-payments
were introduced as a revenue raising measure. Two Irish studies found
both co-payments (€0.50 and €1.50) were associated with larger
reductions in adherence to less--essential medicines than essential
medicines, with anti-depressant and anxiolytic/hypnotic medicines
being the exception [34,35]. In 2013, a number of cost containment
measures were introduced. GMS eligibility income criteria were
lowered, co-payment charges were increased and new legislation was
enacted on reference pricing and generic substitution. These policy
changes will reduce future GMS expenditure.

Limitation
The researchers investigated the possibility of developing estimates
of the variables by the current regional HSE structure, which
incorporates four regions (Dublin Mid-Leinster, Dublin North-East,
and West and South). However, this was not possible for the
Population variable5. Further research investigating the 2013 policy
changes and the impact of the IPHA agreement on GMS expenditure
would be very useful.

Conclusion
Growth in population and population aging will contribute to future
GMS expenditure through the channels of increased average cost per
claimant, GMS coverage and claims rates. However, cost containment
measures; co-payment charges, generic substitution, reference pricing
and GMS eligibility criteria can decelerate the pace of GMS
expenditure growth. Co-payment charges are likely to reduce claims
rates. Reference pricing and generic substitution are likely to reduce
average cost per claimant and eligibility criteria will lower GMS

Minister for Health, James Reilly stated a breakdown in projected savings was not available by community drug scheme.
Personal Communication: with a CSO population Statistician and we were advised that the population data was only available by county
but we required further disaggregation. For example, North Tipperary resides in HSE West and South Tipperary resides in HSE South.
Therefore the research was based on the 8 old health board regions when further disaggregation was not available.
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coverage rates. The health sector in Ireland has a rapidly changing
policy environment and this research went in some way to address
these changes given the data that was at our disposal.
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